DD152548A1 - Verfahren zur herstellung von therapeutisch wirksamen imidazolen - Google Patents
Verfahren zur herstellung von therapeutisch wirksamen imidazolen Download PDFInfo
- Publication number
- DD152548A1 DD152548A1 DD80223182A DD22318280A DD152548A1 DD 152548 A1 DD152548 A1 DD 152548A1 DD 80223182 A DD80223182 A DD 80223182A DD 22318280 A DD22318280 A DD 22318280A DD 152548 A1 DD152548 A1 DD 152548A1
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- formula
- compound
- imidazole
- hydrogen
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 150000002460 imidazoles Chemical class 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 32
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims abstract description 7
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 6
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 146
- 150000001875 compounds Chemical class 0.000 claims description 85
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 30
- -1 hydroxy, amino Chemical group 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000468 ketone group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 241000251730 Chondrichthyes Species 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 150000007978 oxazole derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 8
- 230000000767 anti-ulcer Effects 0.000 abstract description 6
- 101100072620 Streptomyces griseus ind2 gene Proteins 0.000 abstract 4
- 101100072621 Streptomyces griseus ind7 gene Proteins 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 238000002844 melting Methods 0.000 description 45
- 230000008018 melting Effects 0.000 description 45
- 239000000203 mixture Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- ZOMATQMEHRJKLO-UHFFFAOYSA-N 1h-imidazol-2-ylmethanol Chemical compound OCC1=NC=CN1 ZOMATQMEHRJKLO-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 150000003840 hydrochlorides Chemical class 0.000 description 18
- 235000011121 sodium hydroxide Nutrition 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000002026 chloroform extract Substances 0.000 description 9
- 239000000155 melt Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 229910017604 nitric acid Inorganic materials 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 150000001555 benzenes Chemical class 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001624 sedative effect Effects 0.000 description 5
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 4
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 4
- XFLFAULFAINCDT-UHFFFAOYSA-N 2-(ethoxymethyl)-1h-imidazole Chemical compound CCOCC1=NC=CN1 XFLFAULFAINCDT-UHFFFAOYSA-N 0.000 description 4
- WBQTVZALNOJHNB-UHFFFAOYSA-N 2-(methoxymethyl)-1h-imidazole Chemical compound COCC1=NC=CN1 WBQTVZALNOJHNB-UHFFFAOYSA-N 0.000 description 4
- ZNZBCEFJSNGEIV-UHFFFAOYSA-N 5-[(2-methylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC=CC=C1CC1=CN=CN1 ZNZBCEFJSNGEIV-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- VVBODOHHTDMGEI-UHFFFAOYSA-N (5-methyl-1h-imidazol-4-yl)-(2-methylphenyl)methanone Chemical compound N1C=NC(C(=O)C=2C(=CC=CC=2)C)=C1C VVBODOHHTDMGEI-UHFFFAOYSA-N 0.000 description 3
- SUNOGDFMRGHAHP-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-2-oxopropanal Chemical compound ClC1=CC=CC(Cl)=C1CC(=O)C=O SUNOGDFMRGHAHP-UHFFFAOYSA-N 0.000 description 3
- YUIXJMDBSJGFOZ-UHFFFAOYSA-N 5-[(2-chlorophenyl)methyl]-1h-imidazole Chemical compound ClC1=CC=CC=C1CC1=CN=CN1 YUIXJMDBSJGFOZ-UHFFFAOYSA-N 0.000 description 3
- SSXNHDVBINJCKY-UHFFFAOYSA-N 5-[(3-methylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC=CC(CC=2NC=NC=2)=C1 SSXNHDVBINJCKY-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 238000003747 Grignard reaction Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000006178 methyl benzyl group Chemical group 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WFBGZENYPHWNOX-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-3-hydroxypropan-2-one Chemical compound OCC(=O)CC1=C(Cl)C=CC=C1Cl WFBGZENYPHWNOX-UHFFFAOYSA-N 0.000 description 2
- RMMXQNXOSRCWFX-UHFFFAOYSA-N 1h-imidazol-5-yl-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)C1=CNC=N1 RMMXQNXOSRCWFX-UHFFFAOYSA-N 0.000 description 2
- JDMFXJULNGEPOI-UHFFFAOYSA-N 2,6-dichloroaniline Chemical compound NC1=C(Cl)C=CC=C1Cl JDMFXJULNGEPOI-UHFFFAOYSA-N 0.000 description 2
- UVOCKSMHKPRDMY-UHFFFAOYSA-N 2-[(2-methylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC=CC=C1CC1=NC=CN1 UVOCKSMHKPRDMY-UHFFFAOYSA-N 0.000 description 2
- MYMYVYZLMUEVED-UHFFFAOYSA-N 2-bromo-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1Br MYMYVYZLMUEVED-UHFFFAOYSA-N 0.000 description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- HREUGOAZLRNTEM-UHFFFAOYSA-N 5-benzyl-1h-imidazole Chemical group C=1C=CC=CC=1CC1=CN=CN1 HREUGOAZLRNTEM-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010049816 Muscle tightness Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ADSXDBCZNVXTRD-UHFFFAOYSA-N [Mg]C1=CC=CC=C1 Chemical class [Mg]C1=CC=CC=C1 ADSXDBCZNVXTRD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- RHDJRPPFURBGLQ-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2NC=NC=2)=C1C RHDJRPPFURBGLQ-UHFFFAOYSA-N 0.000 description 2
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 2
- 125000006182 dimethyl benzyl group Chemical group 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical class O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- JMVUPSSDLJUEEE-UHFFFAOYSA-N (2,6-dimethyl-3-nitrophenyl)-(1h-imidazol-5-yl)methanone Chemical compound CC1=CC=C([N+]([O-])=O)C(C)=C1C(=O)C1=CNC=N1 JMVUPSSDLJUEEE-UHFFFAOYSA-N 0.000 description 1
- BZNNICSLFSDPRC-UHFFFAOYSA-N (5-phenyl-1h-imidazol-2-yl)methanol Chemical compound N1C(CO)=NC(C=2C=CC=CC=2)=C1 BZNNICSLFSDPRC-UHFFFAOYSA-N 0.000 description 1
- FBVBZMVMEANWQE-UHFFFAOYSA-N 1,3-dichloro-2-propylbenzene Chemical compound CCCC1=C(Cl)C=CC=C1Cl FBVBZMVMEANWQE-UHFFFAOYSA-N 0.000 description 1
- YTSAXRHXEZYMID-UHFFFAOYSA-N 1-[4-[(2,3-dimethylphenyl)methyl]imidazol-1-yl]ethanone Chemical compound CC(=O)N1C=NC(CC=2C(=C(C)C=CC=2)C)=C1 YTSAXRHXEZYMID-UHFFFAOYSA-N 0.000 description 1
- DRKWDLPLONLRBU-UHFFFAOYSA-N 1-benzyl-4-[(2-methylphenyl)methyl]imidazole Chemical compound CC1=CC=CC=C1CC(N=C1)=CN1CC1=CC=CC=C1 DRKWDLPLONLRBU-UHFFFAOYSA-N 0.000 description 1
- KKKDZZRICRFGSD-UHFFFAOYSA-N 1-benzylimidazole Chemical compound C1=CN=CN1CC1=CC=CC=C1 KKKDZZRICRFGSD-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
- NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- DECHVIXTYBTMBL-UHFFFAOYSA-N 1h-imidazol-5-yl(phenyl)methanone Chemical class C=1C=CC=CC=1C(=O)C1=CN=CN1 DECHVIXTYBTMBL-UHFFFAOYSA-N 0.000 description 1
- RQEVOUAOUXHESN-UHFFFAOYSA-N 1h-imidazol-5-yl-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CN=CN1 RQEVOUAOUXHESN-UHFFFAOYSA-N 0.000 description 1
- PDFGFQUSSYSWNI-UHFFFAOYSA-N 2-(bromomethyl)-1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1CBr PDFGFQUSSYSWNI-UHFFFAOYSA-N 0.000 description 1
- HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 description 1
- HBZHCGKSSDKJIJ-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-1h-imidazole Chemical compound ClC1=CC=CC(Cl)=C1CC1=NC=CN1 HBZHCGKSSDKJIJ-UHFFFAOYSA-N 0.000 description 1
- NIRASHDWADNQJU-UHFFFAOYSA-N 2-[(2,6-diethylphenyl)methyl]-1h-imidazole Chemical compound CCC1=CC=CC(CC)=C1CC1=NC=CN1 NIRASHDWADNQJU-UHFFFAOYSA-N 0.000 description 1
- CGYRZILXCROPRH-UHFFFAOYSA-N 2-[(2-chlorophenyl)methyl]-1h-imidazole Chemical compound ClC1=CC=CC=C1CC1=NC=CN1 CGYRZILXCROPRH-UHFFFAOYSA-N 0.000 description 1
- WEBHANPDPWMNQH-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methyl]-1H-imidazole Chemical compound COC=1C=C(CC=2NC=CN=2)C=CC=1 WEBHANPDPWMNQH-UHFFFAOYSA-N 0.000 description 1
- TUTPQCNQVCZJNF-UHFFFAOYSA-N 2-chloro-3-[(2-methylphenyl)methyl]oxirane Chemical compound CC1=CC=CC=C1CC1C(Cl)O1 TUTPQCNQVCZJNF-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- OFMBSIAKTAZWIE-UHFFFAOYSA-N 2-oxo-3-phenylpropanal Chemical compound O=CC(=O)CC1=CC=CC=C1 OFMBSIAKTAZWIE-UHFFFAOYSA-N 0.000 description 1
- YNCJXPAIRULCGX-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-2,2-diethoxypropanal Chemical compound CCOC(C=O)(OCC)CC1=C(Cl)C=CC=C1Cl YNCJXPAIRULCGX-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- APZXPRHPPCTRHN-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1h-imidazole Chemical compound CC=1NC=NC=1CCl APZXPRHPPCTRHN-UHFFFAOYSA-N 0.000 description 1
- FQOYSVIMWGYYJB-UHFFFAOYSA-N 4-[(2,6-dimethylphenyl)methyl]-5-methyl-1h-imidazole Chemical compound N1C=NC(CC=2C(=CC=CC=2C)C)=C1C FQOYSVIMWGYYJB-UHFFFAOYSA-N 0.000 description 1
- QOGHRLGTXVMRLM-UHFFFAOYSA-N 4-bromo-1,2-dimethylbenzene Chemical compound CC1=CC=C(Br)C=C1C QOGHRLGTXVMRLM-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- HCGYTFXTHWTYFK-UHFFFAOYSA-N 5-(chloromethyl)-1h-imidazole Chemical compound ClCC1=CN=CN1 HCGYTFXTHWTYFK-UHFFFAOYSA-N 0.000 description 1
- CHPYZDMYLNLQIY-UHFFFAOYSA-N 5-(ethoxymethyl)-1h-imidazole Chemical compound CCOCC1=CN=CN1 CHPYZDMYLNLQIY-UHFFFAOYSA-N 0.000 description 1
- HVNZZQUYLBKIIJ-UHFFFAOYSA-N 5-[(2,4-dimethylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC(C)=CC=C1CC1=CN=CN1 HVNZZQUYLBKIIJ-UHFFFAOYSA-N 0.000 description 1
- WWEDEECRSOOIGH-UHFFFAOYSA-N 5-[(2,6-dimethylphenyl)methyl]-1h-imidazole Chemical compound CC1=CC=CC(C)=C1CC1=CN=CN1 WWEDEECRSOOIGH-UHFFFAOYSA-N 0.000 description 1
- HHUQCBREJLPRJC-UHFFFAOYSA-N 5-[(2-ethylphenyl)methyl]-1h-imidazole Chemical compound CCC1=CC=CC=C1CC1=CN=CN1 HHUQCBREJLPRJC-UHFFFAOYSA-N 0.000 description 1
- AMHFVWFYEUUITF-UHFFFAOYSA-N 5-[(2-methoxyphenyl)methyl]-1h-imidazole Chemical compound COC1=CC=CC=C1CC1=CNC=N1 AMHFVWFYEUUITF-UHFFFAOYSA-N 0.000 description 1
- JTBXLJUAKPIMRF-UHFFFAOYSA-N 5-[(2-methylphenyl)methyl]-1H-imidazole 5-[(3-methylphenyl)methyl]-1H-imidazole Chemical compound CC=1C=C(CC=2N=CNC2)C=CC1.CC1=C(CC=2N=CNC2)C=CC=C1 JTBXLJUAKPIMRF-UHFFFAOYSA-N 0.000 description 1
- AXOOMPZRPCHHAS-UHFFFAOYSA-N 5-[(3-methoxyphenyl)methyl]-1h-imidazole Chemical compound COC1=CC=CC(CC=2N=CNC=2)=C1 AXOOMPZRPCHHAS-UHFFFAOYSA-N 0.000 description 1
- ZJIHGPSTWADKHO-UHFFFAOYSA-N 5-[(4-methoxyphenyl)methyl]-1h-imidazole Chemical compound C1=CC(OC)=CC=C1CC1=CN=CN1 ZJIHGPSTWADKHO-UHFFFAOYSA-N 0.000 description 1
- KMWCSNCNHSEXIF-UHFFFAOYSA-N 5-methyl-1h-imidazole-4-carbaldehyde Chemical compound CC=1N=CNC=1C=O KMWCSNCNHSEXIF-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VKSPIPWLHGKJQO-UHFFFAOYSA-N Bupicomide Chemical compound CCCCC1=CC=C(C(N)=O)N=C1 VKSPIPWLHGKJQO-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241001475178 Dira Species 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001026509 Kata Species 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010083387 Saralasin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- VOUJGMNCBNTBPT-UHFFFAOYSA-N [5-(2-methoxyphenyl)-1H-imidazol-2-yl]methanol Chemical compound COC1=CC=CC=C1C1=CN=C(CO)N1 VOUJGMNCBNTBPT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229950008162 bupicomide Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- IDGRFJQRPSMHHP-UHFFFAOYSA-N methyl 5-methyl-1h-imidazole-4-carboxylate Chemical compound COC(=O)C=1N=CNC=1C IDGRFJQRPSMHHP-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical class Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- PFGWGEPQIUAZME-NXSMLHPHSA-N saralasin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 PFGWGEPQIUAZME-NXSMLHPHSA-N 0.000 description 1
- 229960004785 saralasin Drugs 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CVWILQHZFWRYPB-UHFFFAOYSA-N tiamenidine Chemical compound CC1=CSC(Cl)=C1NC1=NCCN1 CVWILQHZFWRYPB-UHFFFAOYSA-N 0.000 description 1
- 229950000164 tiamenidine Drugs 0.000 description 1
- 229950011585 timoprazole Drugs 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/48—Preparation of compounds having groups
- C07C41/50—Preparation of compounds having groups by reactions producing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/313—Compounds having groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
- C07C45/515—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an acetalised, ketalised hemi-acetalised, or hemi-ketalised hydroxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
- C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/258—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6457579A | 1979-08-07 | 1979-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD152548A1 true DD152548A1 (de) | 1981-12-02 |
Family
ID=22056899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD80223182A DD152548A1 (de) | 1979-08-07 | 1980-08-07 | Verfahren zur herstellung von therapeutisch wirksamen imidazolen |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4443466A (enExample) |
| EP (1) | EP0024829B1 (enExample) |
| JP (1) | JPS5632463A (enExample) |
| AT (1) | ATE7226T1 (enExample) |
| AU (1) | AU518569B2 (enExample) |
| BG (1) | BG60426B2 (enExample) |
| CA (1) | CA1154780A (enExample) |
| DD (1) | DD152548A1 (enExample) |
| DE (1) | DE3067618D1 (enExample) |
| DK (2) | DK155794C (enExample) |
| FI (1) | FI70709C (enExample) |
| HK (1) | HK68587A (enExample) |
| HU (1) | HU184809B (enExample) |
| IE (1) | IE50080B1 (enExample) |
| IL (1) | IL60723A (enExample) |
| NO (1) | NO153220C (enExample) |
| NZ (1) | NZ194536A (enExample) |
| SG (1) | SG34987G (enExample) |
| SU (2) | SU997607A3 (enExample) |
| UA (1) | UA5559A1 (enExample) |
| ZA (1) | ZA804787B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2069481B (en) * | 1980-02-13 | 1983-07-27 | Farmos Oy | Substituted imidazole derivatives |
| US4374843A (en) * | 1980-10-14 | 1983-02-22 | Pfizer Inc. | 2-Guanidino-4-heteroarylthiazoles |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| GB2110663B (en) * | 1981-12-04 | 1985-08-07 | Farmos Group Ltd | Imidazole derivatives |
| FI833794A0 (fi) * | 1983-10-18 | 1983-10-18 | Farmos Oy | Substituerade 2-merkapto-imidazoler |
| JPH0658947B2 (ja) * | 1984-02-24 | 1994-08-03 | 株式会社日立製作所 | 半導体メモリ装置の製法 |
| DE3539629A1 (de) * | 1985-11-08 | 1987-05-14 | Basf Ag | Dialkoxyketone und ein verfahren zu ihrer herstellung |
| GB8626287D0 (en) * | 1986-11-04 | 1986-12-03 | Ucb Sa | Substituted 1h-imidazoles |
| JPS63150266A (ja) * | 1986-12-12 | 1988-06-22 | Mitsui Petrochem Ind Ltd | ベンジルイミダゾ−ル誘導体 |
| GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
| GB8810067D0 (en) * | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
| US5255225A (en) * | 1989-04-05 | 1993-10-19 | Hitachi, Ltd. | Semiconductor integrated circuit device and memory consisting of semiconductor integrated circuit |
| US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
| US5086064A (en) * | 1990-03-27 | 1992-02-04 | Warner-Lambert Company | 3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| ES2076085B1 (es) * | 1993-06-15 | 1997-03-01 | Lilly Co Eli | Antagonistas de angiotensina ii. |
| NZ330898A (en) * | 1993-11-15 | 2000-01-28 | Schering Corp | Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation |
| US5922751A (en) * | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
| KR100385095B1 (ko) * | 1997-07-15 | 2003-08-19 | 주식회사 엘지생명과학 | 파네실전이효소저해효능을갖는2환또는3환방향족화합물 |
| US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6503935B1 (en) | 1998-08-07 | 2003-01-07 | Abbott Laboratories | Imidazoles and related compounds as α1A agonists |
| AU4537400A (en) * | 1999-05-12 | 2000-12-05 | Neurosearch A/S | Ion channel modulating agents |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| JP2002262119A (ja) * | 2001-02-28 | 2002-09-13 | Sharp Corp | 画像処理装置、画像処理方法、画像処理プログラムを記録した機械読取可能な記録媒体および画像処理プログラム |
| FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| ES2543714T3 (es) * | 2005-06-22 | 2015-08-21 | Chemocentryx, Inc. | Compuestos de azaindazol y métodos de uso |
| US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| ES2338716T3 (es) * | 2006-01-27 | 2010-05-11 | F.Hoffmann-La Roche Ag | Uso de derivados de 4-imidazol para trastornos del snc. |
| US20090252779A1 (en) * | 2006-06-22 | 2009-10-08 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| EP2076497B1 (en) | 2006-10-19 | 2012-02-22 | F. Hoffmann-La Roche AG | Aminomethyl-4-imidazoles |
| EP2086959B1 (en) | 2006-11-02 | 2011-11-16 | F. Hoffmann-La Roche AG | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
| JP2010510184A (ja) | 2006-11-16 | 2010-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換４−イミダゾール類 |
| MX2009005920A (es) | 2006-12-13 | 2009-06-16 | Hoffmann La Roche | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| US8013169B2 (en) | 2007-01-12 | 2011-09-06 | Allergan, Inc | Naphthylmethylimidizoles as therapeutic agents |
| WO2008088936A1 (en) * | 2007-01-12 | 2008-07-24 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
| US8119807B2 (en) | 2007-01-12 | 2012-02-21 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
| NZ578260A (en) | 2007-02-02 | 2012-02-24 | Hoffmann La Roche | Novel 2-aminooxazolines as taar1 ligands for cns disorders |
| BRPI0807813A2 (pt) | 2007-02-15 | 2014-08-05 | Hoffmann La Roche | 2-amino-oxazolinas como ligantes de taar1 |
| CN101743238B (zh) | 2007-05-22 | 2014-04-30 | 凯莫森特里克斯股份有限公司 | 3-(咪唑基)-吡唑并[3,4-b]吡啶 |
| EP2173720A2 (en) | 2007-07-02 | 2010-04-14 | F. Hoffmann-Roche AG | 2-imidazolines having a good affinity to the trace amine associated receptors (taars) |
| BRPI0812833A2 (pt) | 2007-07-03 | 2014-12-09 | Hoffmann La Roche | 4-imidazolinas e seu uso como antidepressivos |
| WO2009016048A1 (en) | 2007-07-27 | 2009-02-05 | F. Hoffmann-La Roche Ag | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| BRPI0814758A2 (pt) | 2007-08-03 | 2015-03-03 | Hoffmann La Roche | Piridinacarboxamida e derivados de benzamida como ligantes taar1 |
| BRPI0913019A2 (pt) * | 2008-05-13 | 2015-10-13 | Allergan Inc | naftilmetilimidazóis para o tratamento de incontinência urinária por estresse |
| BRPI0912604A2 (pt) * | 2008-05-13 | 2019-09-10 | Allergan Inc | quinolinilmetilimidazóis como agentes terapêuticos |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| PL2323663T3 (pl) | 2008-09-11 | 2015-08-31 | Chemocentryx Inc | 4-amino-3-(imidazolilo)-pirazolo[3,4,-d]pirymidyny |
| CN101747280B (zh) * | 2008-11-28 | 2011-11-09 | 上海迪赛诺医药发展有限公司 | 制备地托咪定及其中间体的方法 |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| CN101941944A (zh) * | 2010-09-07 | 2011-01-12 | 江阴希迪医药科技有限公司 | 兽药麻醉剂盐酸地托咪啶盐的合成方法 |
| RU2448094C1 (ru) * | 2010-12-09 | 2012-04-20 | Олег Геннадьевич Еремин | Улучшенный способ получения медетомидина или его нетоксичных фармацевтически приемлемых солей |
| RU2448095C1 (ru) * | 2010-12-09 | 2012-04-20 | Олег Геннадьевич Еремин | Способ получения детомидина или его нетоксичных фармацевтически приемлемых солей |
| CA2860099A1 (en) * | 2012-02-13 | 2013-08-22 | Johannes Aebi | Imidazolylketone derivatives asd aldosterone synthase inhibitors |
| RU2478622C1 (ru) * | 2012-02-16 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | (1-гидрокси-4,5-диметил-1н-имидазол-2-ил)(фенил)метаноноксим, проявляющий антиаритмические свойства |
| CN107922399A (zh) * | 2015-07-16 | 2018-04-17 | 内布拉斯加大学董事委员会 | 吡咯霉素及其使用方法 |
| PT3401310T (pt) | 2015-12-25 | 2022-06-02 | Otsuka Pharma Factory Inc | Composto de fenilimidazol |
| HRP20201405T1 (hr) | 2016-03-17 | 2020-11-27 | F. Hoffmann - La Roche Ag | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a |
| CN107814771A (zh) * | 2017-11-14 | 2018-03-20 | 安徽诺全药业有限公司 | 一种盐酸地托咪定的制备方法 |
| WO2020016827A1 (en) * | 2018-07-18 | 2020-01-23 | Clexio Biosciences Ltd. | Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water |
| WO2024200462A1 (en) * | 2023-03-30 | 2024-10-03 | Bayer Aktiengesellschaft | PALLADIUM-CATALYZED CHEMOSELECTIVE MONO-α-ARYLATION OF O-PROTECTED HYDROXYACETONE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE553516A (enExample) * | 1955-12-19 | |||
| US2946804A (en) * | 1958-12-29 | 1960-07-26 | Abbott Lab | (5-methyl-4-imidazolyl)-diphenyl carbinol salts and lower alkyl quaternaries |
| US3177223A (en) * | 1961-12-22 | 1965-04-06 | Air Prod & Chem | Preparation of substituted imidazoles |
| FR2319346A1 (fr) * | 1975-07-31 | 1977-02-25 | Wellcome Found | Medicament comprenant une association d'un agent anti-inflammatoire et d'un imidazole ou d'un benzimidazole |
-
1980
- 1980-03-05 AU AU61071/80A patent/AU518569B2/en not_active Expired
- 1980-08-01 AT AT80302637T patent/ATE7226T1/de not_active IP Right Cessation
- 1980-08-01 FI FI802404A patent/FI70709C/fi not_active IP Right Cessation
- 1980-08-01 NZ NZ194536A patent/NZ194536A/xx unknown
- 1980-08-01 DE DE8080302637T patent/DE3067618D1/de not_active Expired
- 1980-08-01 EP EP80302637A patent/EP0024829B1/en not_active Expired
- 1980-08-01 IL IL60723A patent/IL60723A/xx unknown
- 1980-08-05 IE IE1626/80A patent/IE50080B1/en not_active IP Right Cessation
- 1980-08-06 HU HU801955A patent/HU184809B/hu unknown
- 1980-08-06 UA UA2959548A patent/UA5559A1/uk unknown
- 1980-08-06 ZA ZA00804787A patent/ZA804787B/xx unknown
- 1980-08-06 CA CA000357663A patent/CA1154780A/en not_active Expired
- 1980-08-06 SU SU802959548A patent/SU997607A3/ru active
- 1980-08-06 NO NO802352A patent/NO153220C/no unknown
- 1980-08-06 DK DK338580A patent/DK155794C/da not_active IP Right Cessation
- 1980-08-06 JP JP10878680A patent/JPS5632463A/ja active Granted
- 1980-08-07 DD DD80223182A patent/DD152548A1/de not_active IP Right Cessation
-
1981
- 1981-03-10 US US06/242,234 patent/US4443466A/en not_active Expired - Lifetime
- 1981-05-28 SU SU813289249A patent/SU1014472A3/ru active
-
1986
- 1986-12-29 DK DK630586A patent/DK157491C/da active
-
1987
- 1987-04-14 SG SG34987A patent/SG34987G/en unknown
- 1987-09-24 HK HK685/87A patent/HK68587A/en not_active IP Right Cessation
-
1994
- 1994-01-18 BG BG098381A patent/BG60426B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ194536A (en) | 1983-06-17 |
| JPS624387B2 (enExample) | 1987-01-30 |
| DK157491B (da) | 1990-01-15 |
| NO153220C (no) | 1986-02-05 |
| US4443466A (en) | 1984-04-17 |
| SG34987G (en) | 1988-03-04 |
| ZA804787B (en) | 1981-07-29 |
| ATE7226T1 (de) | 1984-05-15 |
| AU6107180A (en) | 1981-02-12 |
| AU518569B2 (en) | 1981-10-08 |
| DK338580A (da) | 1981-02-08 |
| IE50080B1 (en) | 1986-02-05 |
| BG60426B2 (bg) | 1995-03-31 |
| DK157491C (da) | 1990-06-25 |
| HK68587A (en) | 1987-10-02 |
| FI70709C (fi) | 1986-10-06 |
| DK155794B (da) | 1989-05-16 |
| NO802352L (no) | 1981-02-09 |
| IE801626L (en) | 1981-02-07 |
| SU997607A3 (ru) | 1983-02-15 |
| NO153220B (no) | 1985-10-28 |
| CA1154780A (en) | 1983-10-04 |
| EP0024829B1 (en) | 1984-04-25 |
| DK155794C (da) | 1989-11-06 |
| EP0024829A1 (en) | 1981-03-11 |
| JPS5632463A (en) | 1981-04-01 |
| DK630586A (da) | 1986-12-29 |
| SU1014472A3 (ru) | 1983-04-23 |
| UA5559A1 (uk) | 1994-12-28 |
| DE3067618D1 (en) | 1984-05-30 |
| HU184809B (en) | 1984-10-29 |
| FI802404A7 (fi) | 1981-02-08 |
| DK630586D0 (da) | 1986-12-29 |
| IL60723A (en) | 1985-02-28 |
| FI70709B (fi) | 1986-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD152548A1 (de) | Verfahren zur herstellung von therapeutisch wirksamen imidazolen | |
| DE1493955A1 (de) | Verfahren zur Herstellung substituierter Sulfonanilide | |
| DE2504565A1 (de) | Neue derivate von 1h-imidazo(4,5-c) pyridin-7-carboxylsaeuren und -saeureestern | |
| SU1597096A3 (ru) | Способ получени производных дифенилпропиламина или их фармакологически приемлемых солей | |
| CH626611A5 (enExample) | ||
| DD258230A1 (de) | Substituierte imidazolderivate sowie deren herstellung und verwendung | |
| DD156260A1 (de) | Herstellung von imidazolderivaten | |
| DE2420618C2 (de) | Aminoalkylanilide, Verfahren zu ihrer Herstellung sowie pharmazeutische Zubereitungen, die diese Aminoalkylanilide enthalten | |
| DE2830884C2 (enExample) | ||
| DE3016828A1 (de) | Benzimidazol-derivate, deren herstellung und verwendung sowie diese derivate enthaltende zubereitungen | |
| DE1793383C3 (de) | 4-Cyan-4-phenyl-aminocyclohexane und deren wasserlösliche Salze, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE1670497B2 (de) | Isochinolinderivate und verfahren zu deren herstellung | |
| EP0303920B1 (de) | Neue Benzofuranderivate und diese enthaltende therapeutische Mittel | |
| CH616929A5 (enExample) | ||
| EP0225543A1 (de) | Basisch substituierte Phenylacetaldehyde, ihre Herstellung und diese enthaltende Arzneimittel | |
| DE2724610A1 (de) | 4-phenyl-8-amino-tetrahydroisochinoline | |
| DE3248094C1 (de) | 7H-Dibenzo(a,c)cyclohepten-5-on(7)-Derivate,Verfahren zu deren Herstellung und deren Verwendung bei der Bekaempfung psychischer Erkrankungen und von Magen-und/oder Darmgeschwueren | |
| AT357165B (de) | Verfahren zur herstellung von neuen china- zolinderivaten und ihren salzen | |
| DE2145682C3 (de) | 1,4-disubstituierte Piperazin-Derivate und deren Säureadditionsverbindungen | |
| DE1493955C3 (de) | Sulfonanilide und Verfahren zu ihrer Herstellung | |
| AT367742B (de) | Verfahren zur herstellung von neuen substituierten 3-(3'-amino-2'-hydroxypropoxyphenyl)-acrylsaeure derivaten sowie deren saeureadditionssalzen | |
| DE1543344A1 (de) | Verfahren zur Herstellung von neuen 1-Amino-3-aryloxypropanol-2-aethern | |
| AT370406B (de) | Verfahren zur herstellung neuer allylaminderivate und ihrer saeureadditionssalze | |
| DE2227922C3 (de) | Spiroverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2300109A1 (de) | Neue semicarbazide und thiosemicarbazide, ihre herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1 | Published as prov. economic patent | ||
| UW | Conversion of economic patent into exclusive patent | ||
| ENJ | Ceased due to non-payment of renewal fee |